2. Activity Goals

3. Program Overview

5. Final Results: Trial of Vemurafenib + Cobimetinib vs Vemurafenib

6. Phase 3: Dabrafenib and Trametinib (COMBI-d) Study

7. Baseline Activities of Cell Signaling Pathways on Combined BRAF and MEK Inhibition

8. Results From the Combination of BRAF/MEK With PD-L1 Inhibitors

9. Selumetinib vs Temozolomide for Uveal Melanoma

11. Mutations in Uveal Melanoma

12. PRAME Expression: Response to Immunotherapy

13. Comparison Between Uveal Melanomas and Cutaneous Melanoma

15. Mutations in Melanoma

16. MAP-Kinase Pathway and MITF Levels

17. Proinflammatory Signals Contribute to Escape From T-cell Attack

19. MASTERKEY-265: A Phase 1b/3 Study of T-VEC + Pembrolizumab (NCT02263508)

20. Preliminary Efficacy -- Best Overall Response (Unconfirmed)

21. Phase I/2 Study of Epacadostat in Combination With Pembrolizumab

22. Conclusions

24. Two Signals for T-Cell Activation

25. PD-1/PD-L1

26. PD-L1 Expression

27. Response Rates: Immunotherapy for Melanoma

28. Pembrolizumab + Low-Dose Ipilimumab

29. Pooled Analysis of Mucosal Melanoma

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)

33. Abbreviations (cont)